Literature DB >> 20949441

Pain management in children and adolescents with sickle cell disease.

Jeanette M Jerrell1, Avnish Tripathi, James R Stallworth.   

Abstract

In a cohort of 2,194 children with sickle cell disease (SCD) treated in community-based services, we explored the types of medications used to treat vaso-occlusive (VOC) pain episodes, and the relative effectiveness of nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and adjunctive antidepressants or anticonvulsant medications on reducing acute VOC pain visits over time. Pharmacologic treatments for VOC pain consisted mainly of NSAIDs and weak opioids. Significantly more patients with more than 3 inpatient or ER VOC pain visits during their first year of SCD treatment were prescribed stronger opioids, SSRIs, SNRI/heterocyclics, and anticonvulsants. Prescription of both stronger opioids and SSRI antidepressants or anticonvulsants was significantly associated with lower cumulative rates of acute VOC pain visits over time. Using an observational study design and existing clinical data, these findings are intended to illustrate the potential clinical advantages of combining adjunctive antidepressants or anticonvulsants with primary pain medications for relief of acute VOC pain over time.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20949441     DOI: 10.1002/ajh.21873

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

1.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Authors:  Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang
Journal:  Blood Adv       Date:  2020-06-23

2.  Use of anti-inflammatory analgesics in sickle-cell disease.

Authors:  J Han; S L Saraf; J P Lash; V R Gordeuk
Journal:  J Clin Pharm Ther       Date:  2017-07-10       Impact factor: 2.512

3.  Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.

Authors:  Cheedy Jaja; Nadine Barrett; Niren Patel; Matt Lyon; Hongyan Xu; Abdullah Kutlar
Journal:  Genet Test Mol Biomarkers       Date:  2016-08-23

4.  Prevalence and treatment of depression in children and adolescents with sickle cell disease: a retrospective cohort study.

Authors:  Jeanette M Jerrell; Avnish Tripathi; Roger S McIntyre
Journal:  Prim Care Companion CNS Disord       Date:  2011

5.  Coping and coping assistance among children with sickle cell disease and their parents.

Authors:  Aimee K Hildenbrand; Lamia P Barakat; Melissa A Alderfer; Meghan L Marsac
Journal:  J Pediatr Hematol Oncol       Date:  2015-01       Impact factor: 1.289

6.  Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management.

Authors:  Cheedy Jaja; Latanya Bowman; Leigh Wells; Niren Patel; Hongyan Xu; Matt Lyon; Abdullah Kutlar
Journal:  Clin Transl Sci       Date:  2015-02-02       Impact factor: 4.689

7.  Opioid Prescription Filling Trends Among Children with Sickle Cell Disease After the Release of State-Issued Guidelines on Pain Management.

Authors:  Susan E Creary; Deena J Chisolm; Sharon K Wrona; Jennifer N Cooper
Journal:  Pain Med       Date:  2020-10-01       Impact factor: 3.750

8.  CYP2C9 allelic variants and frequencies in a pediatric sickle cell disease cohort: implications for NSAIDs pharmacotherapy.

Authors:  Cheedy Jaja; Niren Patel; Stuart A Scott; Robert Gibson; Abdullah Kutlar
Journal:  Clin Transl Sci       Date:  2014-05-29       Impact factor: 4.689

Review 9.  Pain in sickle cell disease: current and potential translational therapies.

Authors:  Varun Sagi; Aditya Mittal; Huy Tran; Kalpna Gupta
Journal:  Transl Res       Date:  2021-03-09       Impact factor: 10.171

10.  Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis.

Authors:  Silvia R Brandalise; Rosemary Assis; Angelo B A Laranjeira; José Andrés Yunes; Pedro O de Campos-Lima
Journal:  Exp Hematol Oncol       Date:  2017-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.